Dr. Blain is the co-founder and CEO of Concarlo Therapeutics, a preclinical oncology company, developing therapeutics for the treatment of drug resistant cancers. Concarlo is an academic spin-out commercializing technology developed in Dr. Blain’s academic lab. Dr. Blain is an internationally recognized expert in the cell cycle and cancer biology, and has been studying the targets that Concarlo is drugging for more than 25 years. Her work has been published in top tier journals; she has presented at numerous national and international meetings, is an ad-hoc reviewer for a dozen different journals, and has been a reviewer for numerous NIH study sections. She has received research funding from the NIH, the American Cancer Society, and the Susan G. Komen Breast Cancer Fund and the METAvivor Foundation. She is a decorated teacher, mentor and educational leader and now has successfully led Concarlo from its academic inception to a company with preclinical assets, currently in manufacturing, with the goal of human clinical trials in 18 months. Dr. Blain received her BA from Princeton University, her Ph.D. from Columbia University, and completed her training at the Memorial Sloan-Kettering Cancer Center. Throughout her career, Dr. Blain has been a huge advocate for Women in STEM, was a finalist in the AIM-HI Women’s Venture Competition, won the RESI Innovator Award, was an Educator of the Year, and was the Girl Scouts of Greater NY Woman of Distinction winner.